Key points from article :
TC BioPharm (Holdings) PLC, a UK-based biotech company listed on NASDAQ, has reported promising early results from its Phase 2B ACHIEVE trial for treating Acute Myeloid Leukemia (AML) with its investigational therapy, TCB008. This treatment is based on gamma-delta T cell technology—a cutting-edge approach that uses immune cells to target cancer. The company announced that the first patient in the latest trial group (Cohort B), who is in remission but still shows minimal residual disease, has completed the full dosing regimen without any serious side effects.
The ACHIEVE trial is being conducted across several UK sites and is currently enrolling more patients. Encouragingly, preliminary data shows that TCB008 has been well tolerated so far, with no cases of cytokine release syndrome or neurotoxicity—two common and serious complications of cell therapies. Executives at TC BioPharm are optimistic about signs of immune system recovery and reduced inflammation in patients.
While the company is making scientific headway, it continues to face financial pressures, reporting a negative EBITDA of $14.3 million over the past year. Despite this, analysts such as H.C. Wainwright maintain a “Buy” rating, though the price target was recently adjusted to $3.00 from $7.00. TC BioPharm is also expanding its platform with potential acquisitions in natural killer (NK) cell and CAR-T technologies, which could enhance the performance of TCB008 in the future.
Although not yet published in a peer-reviewed journal, these updates were shared through a company press release. Lead clinical operations are being overseen by Alison Bracchi, EVP of Clinical Operations. More trial data is expected in late 2025.
